Back

COVID-19 antibody seroprevalence in Duhok, Kurdistan Region, Iraq: A population-based study

Hussein, N. R.; Balatay, A.; Naqid, I. A.; Jamal, S. A.; Rasheed, N. A.; Ahmed, A. N.; Salih, R. S.; Mahdi, A. S.; Mansour, S. A.; Mahdi, S.; Ibrahim, N.; Musa, D. H.; Saleem, Z. S.

2021-03-26 infectious diseases
10.1101/2021.03.23.21254169 medRxiv
Show abstract

ObjectiveThis population-based study aimed to evaluate the seroprevalence of antibodies to SARS-CoV-2 in Duhok City, Kurdistan Region of Iraq. MethodsWe analyzed the national COVID-19 database that contains data regarding COVID-19 testing, management, and clinical outcomes in Duhok. For this study, different subdistricts within each district of Duhok were considered distinct clusters. Blood samples were collected from and questionnaires were administered to eligible and consenting participants who were members of different families from the subdistricts. Immunoassays were conducted to detect antibodies against SARS-CoV-2, and the associations between certain variables were investigated. ResultsThe average number cases of COVID-19 before November 2020 was 23141 {+/-} 4364, which was significantly higher than the average number of cases between November 2020 and February 2021 (3737 {+/-} 2634; P = 0.001). A total of 743 individuals agreed to participate and were enrolled in the study. Among the participants, 465/743 (62.58%) were found to have antibodies against severe acute respiratory syndrome coronavirus 2. Among the participants with antibodies, 262/465 (56.34%) denied having any history of COVID-19-related symptoms. The most common symptom was fever (81.77%), followed by myalgia (81.28%). We found that antibody levels increased steadily with age (Pearson correlation coefficient = 0.117; P = 0.012). A significant association was found between antibody levels and the presence of symptoms (P = 0.023; odds ratio = 1.0023; 95% confidence interval = 1.0002-1.0061). ConclusionsA significant reduction in the number of COVID-19 cases was observed. This might be due to the high prevalence of SARS-CoV-2 antibodies in Duhok. However, infection-prevention measures should be followed as it remains unclear whether acquired immunity is protective against reinfection. It expected that the infection rates during the next wave will not be as high as the first wave due to the high infection rate in the society.

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

1
International Journal of Infectious Diseases
126 papers in training set
Top 0.1%
18.8%
2
PLOS ONE
4510 papers in training set
Top 9%
18.8%
3
Scientific Reports
3102 papers in training set
Top 30%
4.0%
4
Frontiers in Public Health
140 papers in training set
Top 2%
3.6%
5
BMC Infectious Diseases
118 papers in training set
Top 2%
2.8%
6
International Journal of Environmental Research and Public Health
124 papers in training set
Top 2%
2.8%
50% of probability mass above
7
Epidemiology and Infection
84 papers in training set
Top 0.8%
2.6%
8
Journal of Medical Virology
137 papers in training set
Top 1%
2.1%
9
BMJ Open
554 papers in training set
Top 8%
1.9%
10
Frontiers in Medicine
113 papers in training set
Top 3%
1.7%
11
Emerging Infectious Diseases
103 papers in training set
Top 1%
1.7%
12
IJID Regions
10 papers in training set
Top 0.1%
1.7%
13
Journal of Infection and Public Health
15 papers in training set
Top 0.2%
1.5%
14
Travel Medicine and Infectious Disease
15 papers in training set
Top 0.3%
1.3%
15
The American Journal of Tropical Medicine and Hygiene
60 papers in training set
Top 3%
1.3%
16
Vaccines
196 papers in training set
Top 2%
1.3%
17
PLOS Global Public Health
293 papers in training set
Top 4%
1.2%
18
PeerJ
261 papers in training set
Top 10%
1.2%
19
EClinicalMedicine
21 papers in training set
Top 0.6%
1.0%
20
Open Forum Infectious Diseases
134 papers in training set
Top 2%
0.9%
21
Journal of Family Medicine and Primary Care
10 papers in training set
Top 0.5%
0.9%
22
Cureus
67 papers in training set
Top 4%
0.9%
23
Frontiers in Cellular and Infection Microbiology
98 papers in training set
Top 6%
0.8%
24
PLOS Neglected Tropical Diseases
378 papers in training set
Top 5%
0.7%
25
Science China Life Sciences
26 papers in training set
Top 2%
0.7%
26
Public Health
34 papers in training set
Top 2%
0.7%
27
Journal of Clinical Investigation
164 papers in training set
Top 7%
0.7%
28
Frontiers in Immunology
586 papers in training set
Top 9%
0.7%
29
Heliyon
146 papers in training set
Top 8%
0.7%
30
Archives of Clinical and Biomedical Research
28 papers in training set
Top 3%
0.7%